SG
KRYS icon

Stonnington Group’s Krystal Biotech KRYS Stock Holding History

Stonnington Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$276K Buy
+3,100
New +$244K 0.07% 199

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Stonnington Group's KRYS Position: Q1 2023 in Review

Stonnington Group opened a new position in Krystal Biotech (KRYS) in Q1 2023: 3,100 shares worth $276K. The stake represents 0.07% of the portfolio and ranks #199 among its holdings.

160 funds tracked by Wall St. Rank hold KRYS as of Q1 2023.

  • Stonnington Group held 3,100 shares of Krystal Biotech worth $276K as of Q1 2023.
  • Krystal Biotech was a new Stonnington Group position in Q1 2023.
  • Krystal Biotech made up 0.07% of Stonnington Group's portfolio in Q1 2023, its #199 holding.
  • 160 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.